<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0138-6557</journal-id>
<journal-title><![CDATA[Revista Cubana de Medicina Militar]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Cub Med Mil]]></abbrev-journal-title>
<issn>0138-6557</issn>
<publisher>
<publisher-name><![CDATA[Centro Nacional de Información de Ciencias MédicasEditorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0138-65572020000200002</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Eficacia y seguridad clínica del itolizumab en fase de inducción en pacientes con psoriasis grave]]></article-title>
<article-title xml:lang="en"><![CDATA[Efficacy and clinical safety of Itolizumab in the induction phase in patients with severe psoriasis]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Batista Romagosa]]></surname>
<given-names><![CDATA[Maritza]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gray Lovio]]></surname>
<given-names><![CDATA[Olaine Regla]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Falcón Lincheta]]></surname>
<given-names><![CDATA[Leopoldina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez Alonso]]></surname>
<given-names><![CDATA[Teresita]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mantecón Fernández]]></surname>
<given-names><![CDATA[Beatriz]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Urquiza Rodríguez]]></surname>
<given-names><![CDATA[Aleida]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Almenares Soria]]></surname>
<given-names><![CDATA[Liliana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Saumell Nápoles]]></surname>
<given-names><![CDATA[Yaimarelis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Valls Hung]]></surname>
<given-names><![CDATA[Ana Rosa]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vicente Gómez]]></surname>
<given-names><![CDATA[Isabel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Militar "Dr. Joaquín Castillo Duany"  ]]></institution>
<addr-line><![CDATA[Santiago de Cuba ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital General "Manuel Fajardo"  ]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital Militar Central "Dr. Carlos J. Finlay"  ]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Hospital Clínico Quirúrgico Hermanos Ameijeiras  ]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Hospital Provincial "Manuel Ascunce Domenech"  ]]></institution>
<addr-line><![CDATA[Camaguey ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af6">
<institution><![CDATA[,Centro de Investigaciones Médico Quirúrgicas  ]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af7">
<institution><![CDATA[,Hospital "Dr. Juan Bruno Zayas Alfonso"  ]]></institution>
<addr-line><![CDATA[Santiago de Cuba ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af8">
<institution><![CDATA[,Centro de Inmunología Molecular  ]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2020</year>
</pub-date>
<volume>49</volume>
<numero>2</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S0138-65572020000200002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S0138-65572020000200002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S0138-65572020000200002&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  La psoriasis, enfermedad inflamatoria sistémica de la piel, tiene consecuencias adversas serias para el bienestar físico, mental y social de las personas; sus tratamientos son costosos y con marcados efectos adversos. El itolizumab, anticuerpo monoclonal anti CD6 humanizado, actúa como inmunomodulador de las células T y desempeña un importante papel en su patogénesis.  Objetivo:  Evaluar la eficacia y la seguridad clínica del itolizumab en 80 pacientes con psoriasis vulgar grave.  Métodos:  Se realizó un programa de uso clínico expandido, promovido por el Centro de Inmunología Molecular. La respuesta clínica se midió por el índice de gravedad y área de afectación de psoriasis, y para la eficacia se conjugaron estos elementos con los de seguridad, mediante un análisis clínico complementario de los datos generados durante la fase de inducción. Se emplearon como medidas de resumen los números absolutos, el porciento, el promedio y estadísticas de asociación: las pruebas de correlación de de Pearson, de Friedman y la prueba de Lambda.  Resultados:  El análisis del área de afectación de psoriasis arrojó un rápido y sostenido descenso de sus valores; prevalecieron los eventos adversos relacionados con la administración del producto en investigación, de aparición inmediata, ligeros, muy probables y no serios.  Conclusiones:  El itolizumab es seguro y eficaz en el 96 % de los pacientes psoriásicos graves durante los esquemas de inducción.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  Psoriasis, systemic inflammatory skin disease, has serious adverse consequences for the physical, mental and social well-being of people; its treatments are expensive and with marked adverse effects. Itolizumab, a humanized anti-CD6 monoclonal antibody, acts as an immunomodulator of T cells and plays an important role in its pathogenesis.  Objective:  To evaluate the efficacy and clinical safety of itolizumab in 80 patients with severe psoriasis vulgaris.  Methods:  An expanded clinical use program was carried out, promoted by the Molecular Immunology Center. The clinical response was measured by the severity index and area of psoriasis involvement and for effectiveness these elements were combined with safety, through a complementary clinical analysis of the data generated during the induction phase. Absolute numbers, percent and average and association statistics such as Pearson's correlation tests or Lambda's test were used as summary measures.  Results:  The area of psoriasis involvement analysis showed a rapid and sustained decrease in its values; adverse events related to the administration of the product under investigation prevailed, light onset, very probable and not serious.  Conclusions:  Itolizumab is safe and effective in 96% of severe psoriatic patients during the induction phase.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[psoriasis grave]]></kwd>
<kwd lng="es"><![CDATA[itolizumab]]></kwd>
<kwd lng="es"><![CDATA[área de afectación de psoriasis]]></kwd>
<kwd lng="es"><![CDATA[ensayo clínico]]></kwd>
<kwd lng="en"><![CDATA[severe psoriasis]]></kwd>
<kwd lng="en"><![CDATA[itolizumab]]></kwd>
<kwd lng="en"><![CDATA[area of psoriasis involvement]]></kwd>
<kwd lng="en"><![CDATA[clinical trial]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>Departamento de medicamentos de uso humano</collab>
<source><![CDATA[Informe de Posicionamiento Terapéutico de Brodalumab (Kyntheum(r)) en psoriasis en placas]]></source>
<year>2018</year>
<publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Agencia española de medicamentos y productos sanitarios]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gudjonsson]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Elder]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Psoriasis]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Fitzpatrick]]></surname>
<given-names><![CDATA[TB]]></given-names>
</name>
<name>
<surname><![CDATA[Eisen]]></surname>
<given-names><![CDATA[AZ]]></given-names>
</name>
<name>
<surname><![CDATA[Wolff]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Freedberg]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
<name>
<surname><![CDATA[Austen]]></surname>
<given-names><![CDATA[KF]]></given-names>
</name>
</person-group>
<source><![CDATA[Dermatología en Medicina General]]></source>
<year>2018</year>
<edition>9na</edition>
<page-range>169-93</page-range><publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Médica Panamericana]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alfonso Trujillo]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Psoriasis vulgar. Estudio descriptivo de 200 pacientes]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Díaz García]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Torres Gemeil]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Torres Barbosa]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Falcón Lincheta]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez Hernández]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev. Cubana Med]]></source>
<year>2002</year>
<volume>41</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Contreras]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Síndrome Metabólico en pacientes con psoriasis de la Cátedra de Dermatología del Hospital de Clínicas]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Di Martino Ortiz]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez Masi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Knopfelmacher]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Bolla de Lezcano]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Samudio]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Mem Inst Investig Cienc Salud]]></source>
<year>2014</year>
<volume>12</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>25-32</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Romero Herraiz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La genética de la psoriasis]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Pereyra Rodríguez]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Med Cutan Iber Lat Am]]></source>
<year>2016</year>
<volume>44</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>159-66</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Esquivel-García]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La psoriasis: de la investigación básica y clínica al desarrollo de nuevos tratamientos]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Estévez-Delgado]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez-Orozco]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Ochoa-Zarzosa]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[García-Pérez]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<source><![CDATA[Gac Med Mex]]></source>
<year>2018</year>
<volume>154</volume>
<page-range>502-8</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Menon]]></surname>
<given-names><![CDATA[Roshni]]></given-names>
</name>
<name>
<surname><![CDATA[Brinda]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[Itolizumab - a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis]]></source>
<year>2015</year>
<volume>8</volume>
<page-range>215-22</page-range><publisher-loc><![CDATA[Pondicherry, India ]]></publisher-loc>
<publisher-name><![CDATA[Clinical, Cosmetic and Investigational Dermatology]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bughani]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Saha]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kuriakose]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Nair]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Sadashivarao]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Venkataraman]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[T cell activation and differentiation are modulated by a CD6 domain 1 antibody Itolizumab]]></article-title>
<source><![CDATA[PLoS ONE]]></source>
<year>2017</year>
<volume>12</volume>
<numero>7</numero>
<issue>7</issue>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Krupashankar]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Dogra]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kura]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Saraswat]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Budamakuntla]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Sumathy]]></surname>
<given-names><![CDATA[TK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of Itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study]]></article-title>
<source><![CDATA[J Am Acad Dermatology]]></source>
<year>2014</year>
<volume>71</volume>
<page-range>484-92</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Consuegra-Fernández]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evidencia clínica y experimental para atacar a los CD6 en trastornos de base inmunológica]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Feng]]></surname>
<given-names><![CDATA[Lin]]></given-names>
</name>
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Lozano]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[Comentarios de autoinmunidad]]></source>
<year>2018</year>
<volume>17</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>493-503</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Izquierdo Cano]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Espinosa Estrada]]></surname>
<given-names><![CDATA[EE]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández Padrón]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ramón Rodríguez]]></surname>
<given-names><![CDATA[LG]]></given-names>
</name>
<name>
<surname><![CDATA[Ávila Cabrera]]></surname>
<given-names><![CDATA[OM]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández Ramírez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anticuerpo monoclonal humanizado Itolizumab (anti-cd6) en síndromes linfoproliferativos cd 6+.Experiencia preliminar]]></article-title>
<source><![CDATA[Revista Cubana de Hematol, Inmunol y Hemoter]]></source>
<year>2014</year>
<volume>30</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>257-64</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="">
<collab>Sociedad Argentina de Dermatología</collab>
<source><![CDATA[Consenso Nacional de Psoriasis: Guía de Tratamiento]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Batista Romagosa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamiento de pacientes con psoriasis vulgar mediante campo electromagnético de extremada baja frecuencia]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Soriano González]]></surname>
<given-names><![CDATA[BI]]></given-names>
</name>
<name>
<surname><![CDATA[Bergues Cabrales]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
</person-group>
<source><![CDATA[MEDISAN]]></source>
<year>2012</year>
<volume>16</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1399</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aira]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[López-Requena]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fuentes]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Urquiza]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 Itolizumab]]></article-title>
<source><![CDATA[mAbs]]></source>
<year>2014</year>
<volume>6</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>782-92</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ortega-Hernández]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Restrepo-López]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Rosero]]></surname>
<given-names><![CDATA[YS]]></given-names>
</name>
<name>
<surname><![CDATA[Úsuga-Úsuga]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Luis Alfonso Correa-Londoño]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Marín-Agudelo]]></surname>
<given-names><![CDATA[ND]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Características epidemiológicas, clínicas e histopatológicas de pacientes con psoriasis y factores asociados con las formas vulgar y pustulosa]]></article-title>
<source><![CDATA[Dermatol Rev Mex]]></source>
<year>2018</year>
<volume>62</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>193-205</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muñoz- Estrada]]></surname>
<given-names><![CDATA[VF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estudio clínico de psoriasis]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Rochin-Tolosa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Valenzuela-Paz]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Trejo Acuña]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Med UAS Nueva época]]></source>
<year>2010</year>
<volume>1</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>12-9</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Padilla Tresierra]]></surname>
<given-names><![CDATA[YD]]></given-names>
</name>
</person-group>
<source><![CDATA[Sobrepeso, hipertensión arterial y diabetes como factores asociados a psoriasis vulgar]]></source>
<year>2016</year>
<publisher-loc><![CDATA[Trujillo, Perú ]]></publisher-loc>
<publisher-name><![CDATA[Hospital Lazarte. Universidad Privada Antenor Orrego]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marrero Chávez]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluación de la seguridad y el efecto terapéutico del Itolizumab en pacientes de Camagüey con psoriasis severa]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Mantecón Fernández]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[López Gutiérrez]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez Martínez]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Cardoso Ramírez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Revista electrónica Dr. Zoilo E. Marinello Vidaurreta]]></source>
<year>2015</year>
<volume>40</volume>
<numero>10</numero>
<issue>10</issue>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anand]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Assudani]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Nair]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Krishnamurthy]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Deodhar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Arumugam]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety, efficacy and pharmacokinetics of T1h, a humanized anti-CD6 monoclonal antibody, in moderate to severe chronic plaque psoriasis - results from a randomized phase II trial]]></article-title>
<source><![CDATA[J Immunology]]></source>
<year>2010</year>
<volume>184</volume>
<numero>1^ssuppl</numero>
<issue>1^ssuppl</issue>
<supplement>suppl</supplement>
<page-range>96.13</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lerman]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Joshi]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Chaturvedi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Aberra]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Dey]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Rodante]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Coronary plaque characterization in psoriasis reveals high-risk features that improve after treatment in a prospective observational study]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2017</year>
<volume>136</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>263-76</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pai]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Pai]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Itolizumab - A New Biologic for Management of Psoriasis and Psoriatic Arthritis]]></article-title>
<source><![CDATA[Case Rep Dermatology]]></source>
<year>2017</year>
<volume>9</volume>
<page-range>141-5</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernández]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Itolizumab, anticuerpo monoclonal humanizado, un tratamiento novedoso para los pacientes con psoriasis severa]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Montero]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Suárez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Cuenca]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Chong]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Anales de la Academia de Ciencias de Cuba]]></source>
<year>2014</year>
<volume>5</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schmitt]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Rosumeck]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Thomaschewski]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Sporbeck]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Haufe]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Nast]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Br J Dermatology]]></source>
<year>2014</year>
<volume>170</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>274-303</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
